You are here: Industry Insights > Market News > Merck KGaA signs deal with Artios Pharma for cancer drugs research

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Merck KGaA signs deal with Artios Pharma for cancer drugs research

expresspharmaDecember 07, 2020

Tag: Merck KGaA , Artios Pharma , cancer

Favorites

Germany’s Merck KGaA has signed a three-year strategic research deal with Artios Pharma to discover and develop up to eight potential targeted treatments for cancer.

Under the agreement, Artios will receive $30 million in up-front and near-term payments, plus double-digit option fees and up to $860 million total milestones per target.

Merck said in a statement it will have the right to opt into exclusive development and commercialisation of compounds on up to eight targets.

Previous:Indifi forays into pharma segment along with Marg ERP

Next:Lilly, UnitedHealth to Study Bamlanivimab in High-risk COVID-19

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Merck KGaA signs deal with Artios Pharma for cancer drugs research | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

100% Pure Natural Anti-cancer Extraction Bitter Apricot Seed Extract

Nimustine hydrochloride 99%min Pharmaceutical API Nitrosourea drugs Anti cancer drugs made in china

Paclitaxel semi-synthetic and natural USP cancer

Chamomile Flower Extract 1% 1.2% 1.6% Apigenin 98% Anti Cancer

Anticancer Product Green tea Extract Powder. Tea Polyphenols

oxaliplatino EP/USP Pharmaceutical API Drug treatment of colorectal cancer made in china

Natural red Chilly Seed oil with 1-10 Capsaicine for lower cholesterol and The prevention of cancer

Hydroxypropyl beta cyclodextrin in the anticancer drug oxaliplatin

Gemcitabine hydrochloride 98.0%min USP34 Pharmaceutical Anti cancer drugs China

anti-cancer product daunorubicin

Merck KGaA signs deal with Artios Pharma for cancer drugs research

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>